Cargando…

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN

SIMPLE SUMMARY: Lipocalin 2 (LCN2) is a proinflammatory mediator increased in the blood of patients with myeloproliferative neoplasms (MPN) and other hematologic malignancies, significantly contributing to MPN disease initiation and progression. Here, we investigated the underlying mechanisms of LCN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tillmann, Stefan, Olschok, Kathrin, Schröder, Sarah K., Bütow, Marlena, Baumeister, Julian, Kalmer, Milena, Preußger, Vera, Weinbergerova, Barbora, Kricheldorf, Kim, Mayer, Jiri, Kubesova, Blanka, Racil, Zdenek, Wessiepe, Martina, Eschweiler, Jörg, Isfort, Susanne, Brümmendorf, Tim H., Becker, Walter, Schemionek, Mirle, Weiskirchen, Ralf, Koschmieder, Steffen, Chatain, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391615/ https://www.ncbi.nlm.nih.gov/pubmed/34439364 http://dx.doi.org/10.3390/cancers13164210

Ejemplares similares

Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells
por: Baumeister, Julian, et al.
Publicado: (2021)

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
por: Han, Lijuan, et al.
Publicado: (2016)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes
por: Olschok, Kathrin, et al.
Publicado: (2021)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
por: Schubert, Claudia, et al.
Publicado: (2019)

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms
por: Kalmer, Milena, et al.
Publicado: (2022)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition
por: Bütow, Marlena, et al.
Publicado: (2022)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing
por: Kirschner, Martin M. J., et al.
Publicado: (2015)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
por: Stegelmann, Frank, et al.
Publicado: (2023)

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
por: Herrmann, Oliver, et al.
Publicado: (2019)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
por: Vieri, Margherita, et al.
Publicado: (2023)

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
por: Gecht, Judith, et al.
Publicado: (2021)

Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy
por: Asimakopoulou, Anastasia, et al.
Publicado: (2016)

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
por: Parting, Oliver, et al.
Publicado: (2020)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
por: Jacobi, Henrike, et al.
Publicado: (2023)

P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
por: Jacobi, Henrike, et al.
Publicado: (2023)

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
por: Koschmieder, Steffen, et al.
Publicado: (2022)

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
por: Crodel, Carl C., et al.
Publicado: (2020)

Human DC3 Antigen Presenting Dendritic Cells From Induced Pluripotent Stem Cells
por: Satoh, Taiki, et al.
Publicado: (2021)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
por: Holl, Kristin, et al.
Publicado: (2023)

Expression Analysis of Lipocalin 2 (LCN2) in Reproductive and Non-Reproductive Tissues of Esr1-Deficient Mice
por: Kessel, Jan C., et al.
Publicado: (2023)

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma
por: Metselaar, Josbert, et al.
Publicado: (2023)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Lipocalin-2 (LCN2) Deficiency Leads to Cellular Changes in Highly Metastatic Human Prostate Cancer Cell Line PC-3
por: Schröder, Sarah K., et al.
Publicado: (2022)

Depletion of Lipocalin 2 (LCN2) in Mice Leads to Dysbiosis and Persistent Colonization with Segmented Filamentous Bacteria
por: Klüber, Patrick, et al.
Publicado: (2021)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

XBP1 promotes NRAS(G12D) pre‐B acute lymphoblastic leukaemia through IL‐7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS
por: Salimi, Azam, et al.
Publicado: (2023)

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
por: Vieri, Margherita, et al.
Publicado: (2023)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
por: Koschmieder, Steffen, et al.
Publicado: (2018)

The effect of lipocalin-2 (LCN2) on apoptosis: a proteomics analysis study in an LCN2 deficient mouse model
por: Wu, Dongming, et al.
Publicado: (2021)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

The role of LCN2 and LCN2-MMP9 in spondylitis radiographic development: gender and HLA-B27 status differences
por: Tsui, Florence W. L., et al.
Publicado: (2022)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients
por: Palmer, Jeanne M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rced7920diegor147bpbi5vt7g